BioLineRx (BLRX) EBITDA (2023 - 2025)
Historic EBITDA for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$1.4 million.
- BioLineRx's EBITDA changed 0.0% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 million, marking a year-over-year change of 0.0%. This contributed to the annual value of -$1.4 million for FY2024, which is 0.0% changed from last year.
- Per BioLineRx's latest filing, its EBITDA stood at -$1.4 million for Q3 2025, which was down 0.0% from -$1.4 million recorded in Q2 2025.
- BioLineRx's EBITDA's 5-year high stood at -$696000.0 during Q1 2024, with a 5-year trough of -$3.2 million in Q4 2024.
- In the last 3 years, BioLineRx's EBITDA had a median value of -$1.4 million in 2023 and averaged -$1.5 million.
- Over the last 5 years, BioLineRx's EBITDA had its largest YoY gain of 5084.75% in 2024, and its largest YoY loss of 12507.06% in 2024.
- Quarter analysis of 3 years shows BioLineRx's EBITDA stood at -$1.4 million in 2023, then crashed by 125.07% to -$3.2 million in 2024, then skyrocketed by 55.57% to -$1.4 million in 2025.
- Its EBITDA stands at -$1.4 million for Q3 2025, versus -$1.4 million for Q2 2025 and -$1.4 million for Q1 2025.